NotesFAQContact Us
Collection
Advanced
Search Tips
Publication Date
In 20250
Since 20240
Since 2021 (last 5 years)0
Since 2016 (last 10 years)0
Since 2006 (last 20 years)1
Descriptor
Patients2
Pharmacology2
Adolescents1
Attention Deficit Disorders1
Children1
Depression (Psychology)1
Drug Therapy1
Hyperactivity1
Psychiatry1
Source
Journal of the American…2
Author
Axelson, David A.2
Birmaher, Boris2
Brent, David A.2
Daviss, W. Burleson2
Perel, James M.2
Rudolph, George R.2
Gilchrist, Richard1
Melhem, Imad1
Nuss, Sharon1
Publication Type
Journal Articles2
Reports - Evaluative1
Reports - Research1
Education Level
Audience
Location
Laws, Policies, & Programs
Assessments and Surveys
What Works Clearinghouse Rating
Showing all 2 results Save | Export
Steady-State Clinical Pharmacokinetics of Bupropion Extended-Release In Youths
Peer reviewed Peer reviewed
Direct linkDirect link
Daviss, W. Burleson; Perel, James M.; Birmaher, Boris; Rudolph, George R.; Melhem, Imad; Axelson, David A.; Brent, David A. – Journal of the American Academy of Child and Adolescent Psychiatry, 2006
Objective: To examine in children and adolescents the 24-hour, steady-state clinical pharmacokinetics of an extended-release (XL) formulation of bupropion (Wellbutrin XL). Method: Subjects were six male and four female patients (ages 11.5-16.2 years) prescribed bupropion XL in morning daily doses of either 150 mg (n = 5) or 300 mg (n = 5) for at…
Descriptors: Pharmacology, Patients, Children, Adolescents
Steady-State Pharmacokinetics of Bupropion SR in Juvenile Patients
Peer reviewed Peer reviewed
Daviss, W. Burleson; Perel, James M.; Rudolph, George R.; Axelson, David A.; Gilchrist, Richard; Nuss, Sharon; Birmaher, Boris; Brent, David A. – Journal of the American Academy of Child and Adolescent Psychiatry, 2005
Objective: To examine the steady-state pharmacokinetic properties of bupropion sustained release (SR) and their potential developmental differences in youths. Method: Eleven boys and eight girls aged 11 to 17 years old were prescribed bupropion SR monotherapy for attention-deficit/hyperactivity disorder (n = 16) and/or depressive disorders (n =…
Descriptors: Psychiatry, Pharmacology, Patients, Hyperactivity